MicroRNAs (miRNAs or miRs) are 18-22-nucleotide non-coding RNAs that have emerged as a new paradigm of epigenetic regulation in both normal development and cellular function, and in the pathogenesis of human disease including cancer. This review summarizes the current literature of mechanism of gene regulation by miRNA and their role in hematopoiesis and leukemogenesis. An understanding of these processes suggests further avenues for research to understand gene regulation and miRNA-based therapeutic approaches.
MicroRNAs regulate gene expression
Discovered in Caenorhabditis elegans in 1993, 1 microRNAs (miRNAs) have emerged as a major mechanism of epigenetic regulation in forms of life as diverse as algae and human beings. Although the number of miRNAs in lower life forms is about 100-200, B1000 miRNAs are predicted to be present in humans. Bioinformatics predicts that about one-third of all protein-coding genes are regulated by miRNAs. Therefore, it is no surprise that miRNAs are being shown to regulate all facets of normal and abnormal cellular activity.
MicroRNA precursors (pre-miRNA) are transcripts that often contain several miRNAs. These are processed by Drosha (a Ribonuclease III) to form pre-miRNAs, B70 nucleotide hairpin structures. Drosha partners include DiGeorge syndrome critical region 8 (DGCR8). 2 After being transported to the cytoplasm by Exportin-5, these pre-miRNAs are processed by Dicer (another Ribonuclease III) into dsRNA with two nucleotide overhangs. 3 Dicer partners include TAR RNA binding protein. 4 Single-strand RNAs from these dsRNA associate with several proteins to form the RNA induced silencing complex (RISC), which is thought to be responsible for regulation of translation of the target genes. 5 Prominent components of the RISC include the argonaute family of proteins. 6 The final effect of the miRNA on a specific target is both sequence specific and context specific. Although a minimum of six nucleotides need to be a perfect match (nucleotide [2] [3] [4] [5] [6] [7] [8] , the preceding and succeeding nucleotides need not be so. In fact, in some instances, a mismatch 'bulge' region seems to be required. Following the bulge, complementarity at nucleotide 13-16 seems to enhance repression of the target. If the sequence is a perfect match, the final result seems to be target mRNA degradation in a manner similar to siRNAinduced gene expression silencing. This seems to be the predominant mechanism in plants. A less than perfect match may result in inefficient translation leading to effective downregulation of the gene, a mechanism more common in animals. [7] [8] [9] Isolated examples of miRNA leading to upregulation of genes have been reported. 10 The mechanism of translational repression is known only partially. 11 The mRNA segments that miRNAs bind seem to be mostly in the 3 0 UTRs of genes. In these regions, typically, several miRNA-binding sequences seem to act in concert. The combined effect of this binding seems to depend on the distance between the binding sequences and the number of binding sequences. 12 However, if these sequences are placed in the 5 0 end or even in the exons, repression still takes place, suggesting that sequence rather than location may be the over-riding factor. 3 0 UTR binding may affect translation both at the initiation step and at the post-initiation translation. It has been shown that reporter genes with the m 7 G-capped mRNA are repressed by miRNAs but not those with internal ribosome entry site sequences, suggesting some effect of miRNAs on initiation. 13 However, some miRNAs cause repression of mRNA with internal ribosome entry site sequences.
14 Also, polysomes cosediment with miRNAs and their target mRNAs, suggesting an influence on the elongation process of translation. 15, 16 Some evidence also exists that miRNA may regulate repression by preventing 60S subunit joining. 17 Early in the investigation of miRNA-mediated gene regulation, the over-riding theme invoked was that miRNAs alter gene expression in animals purely by translational repression. However, an increasing body of evidence suggests that miRNA-mRNA interaction leads to a de-stabilization of mRNA leading to alteration in mRNA levels, albeit modest. Although enough evidence of alteration of transcript levels exists in microarray experiments, 18 the exact mechanism has only been partially elucidated in Drosophila melanogaster and zebrafish. 19, 20 Experiments have shown that the P body protein GW 182 marks the mRNA for decay. This is based on an interaction with Argonaute 1, a key player in miRNA activity. Also, miR-430 induces deadenylation and decay of several mRNA during zebrafish embryogenesis. Therefore, the mechanism of regulation of gene expression by miRNAs is multi-faceted and still being elucidated.
Technologies to investigate the miRNA expression in normal and malignant tissues
The most commonly used high-throughput technique for the genome-wide assessment of miRNA expression levels in a large number of samples is represented by miRNA microarrays.
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SPOTLIGHT
Several technical variants of miRNA arrays have been independently developed in the past few years, and the main differences between them are the oligo-probe design, the probe immobilization chemistry, the sample labeling and the microarray chip signal detection method. miRNA expression analysis can also be assessed by alternative methodologies. For example, the bead-based flow cytometric technique, 24 characterized by highly specific solution-phase probe/target hybridization kinetics, is able to profile only limited subsets of miRNAs (o100 miRNAs/profile) due to the limitations of the colordecoding system per sample; quantitative RT-PCR specific either for precursor miRNA 25 or for active miRNA 26 is a highly sensitive methodology, requiring small amounts of starting material for the rapid and quantitative analysis of a subset of miRNAs, and is excellent for microarray data validation or for the study of a limited number of miRNAs. The miRNA serial analysis of gene expression (miRAGE) approach, the genomewide miRNA analysis with serial analysis of gene expression, 27 is used for both the analysis of known miRNAs and discovery of unknown miRNAs with large amounts of computational and bioinformatics efforts for the analysis of the obtained tagged sequences. The invader assay directly detects specific RNA molecules using an isothermal signal amplification process with a fluorescence resonance energy transfer-based fluorescence readout. 28 The RNA primed, array-based Klenow enzyme assay uses on the slide application of the Klenow fragment of the DNA polymerase I to extend miRNAs hybridized to DNA probes. 29 Generation of small RNA libraries and deep sequencing using a high-throughput approach is another way of identification and relative quantification of miRNAs. 30 Each of these techniques has its strengths and weaknesses (Table 1) , and the confirmatory use of a second independent technique is mandatory at the present time to identify false-positive/negative data for all the different assays undertaken.
miRNAs regulate hematopoiesis
The hematopoietic system is a good model because of the principle that a common progenitor cell can give rise to cells of different lineages. This process of commitment is governed by the alteration in expression of several genes together. Given the ability of a single miRNA to control the expression of several genes, it is conceptually attractive to propose that miRNAs regulate this process ( Figure 1 ).
Lymphoid development
The first evidence that miRNAs may be involved in regulation of hematopoiesis came from Chen et al. 31 In a series of The role of microRNA in human leukemia S Yendamuri and GA Calin experiments they showed that different hematopoietic tissues had different levels of expression of three miRNAs: miR-181, miR-223 and miR-142. Although miR-181 was strongly expressed in tissues rich in lymphocytes, miR-223 was exclusively expressed in the bone marrow. miR-142 was expressed in all hematopoietic tissues, with no expression in non-hematopoietic tissues. On further expression studies in lineage-specific cells, it was clear that miR-181 was highly expressed in B lymphocytes compared with non-committed cells. miR-223 expression was restricted to cells of myeloid origin. miR-142 was highest in B-lymphoid and myeloid lineages. In order to elucidate the cause and effect versus association, each of the above miRNAs was overexpressed in non-committed cells. With the overexpression of miR-181, as expected there was an increase in the proportion of cells with the B-lymphoid lineage. However, with miR-142 and miR-223, there was an increase in the proportion of T-lymphoid cells and a modest alteration in the proportion of myeloid cells. The results with miR-181 were duplicated in vivo, giving further supportive evidence of their role. In-vivo experiments showed not only an increase in the proportion of B lymphocytes, but also a decrease in T lymphocytes, particularly in the CD8 þ subpopulation. The actual mechanism of action of miR-181 was elucidated in other experiments, which revealed that this effect is achieved by alterations in the level of Bcl-2, CD69 and TCR-alpha. 32 Further influences on the development of lymphocytes have been proposed on the basis of transgenic mouse models. Overexpression of miR-150 led to the blockade of B lymphocytes in experiments reported by Xiao et al. 33 Also, selective deletion of the miR17-92 cluster prevents the transition of pro-B to pre-B cells by an increase in the pro-apoptotic factor Bim. 34 Similar differences in the expression profiles were found during the development of other hematopoietic cells. In several of these, specific alterations in the miRNAs have been associated with alterations in their targets, and distinct pathways controlling the regulation of this process have been identified. These are summarized below.
SPOTLIGHT
Myeloid development
The decision regarding whether a common myeloid progenitor will differentiate into a granulocyte or a monocyte seems to be controlled by miR-223. miR-223 is highly expressed in the granulocyte fraction of the myeloid cells and seems to be repressed in the monocyte component. 35 Using an acute promyelocytic leukemia cell-line model, an auto-regulation model of miR-223 has been proposed. A C/EBPa-binding site has been located upstream of the miR-223 gene in this model. C/EBPa competes with another transcription factor, NFIA (a CCAAT-box binding transcription factor), for this site. Retinoic acid, which induces a progenitor cell to differentiate into a granulocyte, leads to the replacement of NFIA with C/EBPa, leading to activation of miR-223. Given that NFIA is in itself a target of miR-223, an auto-regulatory loop can be conceived. An alternative regulatory mechanism for this process has also been delineated by Fukao et al. 36 These investigators found a PU.1 and C/EBPb-binding site capable of activating miR-223 transcription in mice. The PU.1-binding site is conserved in humans, making this a strong candidate for the control of miR-223 expression. miR-223 seems to act through the regulation of expression of MEF2c, which is a known promoter of granulocyte differentiation.
TPA-induced monocyte/macrophage differentiation of the cell line HL60 induces a specific miRNA expression pattern. One of the miRNAs overexpressed during this differentiation is miR-424, which is located on chromosome X. 37 The expression of miR-424 is also controlled by PU.1. miR-424 acts at least partially by repression of NFIA. 38 
Megakaryocyte development
Garzon et al. 39 showed that differentiation into the megakaryocytic lineage is associated with the downregulation of several miRNAs. Prominent among them are miR-10-a and miR-130a. They also showed that these miRNAs downregulated mafB and HOXA-1, respectively, providing a mechanism for this biological effect. Using a novel method of miRNA profiling capable of generating a usable profile with as low as 10 ng of RNA, Lu et al. 40 showed an overexpression of miR-150 in cells differentiated into the megakaryocytic lineage. Overexpression of miR-150 in megakaryocyte-erythrocyte progenitor cells led to a preferential differentiation toward the megakaryocytic lineage both in vitro and in vivo. This effect is mediated by repression of MYB, which is a known critical target of miR-150. Labbaye et al. 41 have dissected out another molecular pathway controlling megakaryopoiesis. They have shown that the PLZF transcription factor downregulates miR-146a. Downregulation of miR-146a leads to overexpression of the CXCR4 protein (an SDF-1 receptor), which enhances megakaryocytic proliferation, differentiation and maturation.
Erythrocyte development
Felli et al. 42 studied miRNA expression patterns during erythrocyte differentiation. Downregulation of miR-221 and miR-222, which leads to increased kit, expression encouraged expansion of erythrocyte progenitors. Bruchova et al. 43 showed that as differentiation proceeds along the erythrocyte differentiation pathway, there is a downregulation of miR-221, miR-222, miR-155 and miR150, and an upregulation of miR-16 and miR-451. These results were confirmed in a study by Masaki et al. 44 
miRNAs regulate leukemopoiesis
Given the extensive regulation of normal hematopoietic development by miRNA, it is no surprise that miRNAs are extensively involved in the pathogenesis of hematopoietic malignancies. In fact, the first convincing evidence of the role of miRNAs in human cancer was found in the pathogenesis of chronic lymphocytic leukemia (CLL). 45 The following section summarizes the known findings of miRNAs in hematopoietic malignancies.
Lymphomas
MiR-155 has been extensively studied in lymphomas. Apart from being overexpressed in Hodgkin's, primary mediastinal and B-cell lymphomas, 46 ,47 other lines of evidence points to its oncogenic role. MiR-155 seems to be generated by alternative splicing of the non-protein coding BIC region. In transgenic mice overexpressing miR-155, there is a polyclonal expansion of pre-B cells followed by B-cell malignancy, presumably by a second transforming event that the miR-155 overexpression predisposes to. 48 MiR-155 expression is highest in the activated B-cell type of diffuse large B-cell lymphomas and overexpression is associated with downregulation of 42 genes, 11 of which are predicted by miRNA prediction algorithms. Included in these genes are KLRK1, AKAP10 and CSNK1G2, which have been linked to the malignant phenotype of diffuse B-cell
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The role of microRNA in human leukemia S Yendamuri and GA Calin lymphomas. 49 Detection of miR-155 in the sera of patients has also been proposed as a diagnostic test. 50 Overexpression of the miR17-92 cluster in mice leads to the development of a lymphoproliferative disease and death. This is secondary to the downregulation of PTEN and Bim. 51 This region is commonly amplified in B-cell lymphoma patients. 52 The promoter region of this polycistronic cluster has E2F transcription factor binding sites that bind primarily to E2F3. This leads to a potential model in which the miR-17-92 is placed in a regulatory loop between its regulator E2F3 and its target E2F1, which is a pro-apoptotic factor. Therefore, overexpression of the cluster can move the cells toward a proliferative mode in this balance. 53 The overexpression of this polycistronic cassette and the myc oncogene leads to a synergistic cancer development. 54 In Reed-Sternberg cells characteristic of Hodgkin's cells, it has been shown that miR-9 and miR-7a lead to a downregulation of PRDM1/blimp-1 activity and may contribute to the maintenance of the malignant phenotype of these cells. 55 Chromosomal analysis of a fragile site in chromosome 12 in radiation-induced T-cell lymphomas has shown that this region is the home to 52 miRNAs. At least one of these miRNAs seems to be mechanistically involved in the pathogenesis of these tumors. MiR-203 seems to be regulated by hypermethylation. Increased miR-203 leads to repression of ABL1, a well-known oncogene, suggesting a potential therapeutic target.
56 New miRNAs have also been found at the PVT1 locus, which is found in 20% of Burkitt's lymphoma. This region has seven miRNAs (including mmu-miR-1204 and mmu-miR-1206), all of which are expressed at a higher level in late-stage B cells, suggesting potential roles in lymphoma. 57 The let-7a miRNA has also been implicated in the maintenance of the Burkitt's lymphoma phenotype by influencing myc expression. 58 Downregulation of miR-143 and miR-145 has also been shown in Burkitt's lymphoma tissues and may contribute to their pathogenesis through their effect on ERK5. 59 
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia is a disease that has shown distinct alterations in the 13q14 region, suggesting the presence of a tumor suppressor in this region. There is also an overexpression of bcl-2 in these cells. Although this overexpression is explained in some patients by the juxtaposition of the bcl-2 gene to the immunoglobin regions, this translocation is responsible for bcl-2 overexpression in only about 5% of the cases. Given the presence of miR-15a and miR-16-1 in the 13q14 region and that bcl-2 is a predicted target of this cluster, the association was further explored. 45 Cimmino et al. 60 did indeed find that this cluster regulated bcl2 expression.Further exploration of the genome-wide effects of the cluster overexpression in a CLL cell line by analysis of the transcriptome and the proteome after overexpression revealed several interesting results. 61 Overexpression of the miR-15a/mR-16-1 cluster led to a downregulation of 3307 genes and an upregulation of 265 genes. As AU rich elements (ARE)-mediated instability has been implicated in the regulation of gene expression by miR-16-1, the prevalence of AREs in the downregulated genes was explored. In all, 20.1% (666/3307) of the downregulated genes had ARE elements. Analysis of the proteomic changes involved revealed 27 different proteins that showed at least a four-fold change. Prominent among these changes are BCL-2 and WT1, in accordance with prediction patterns and earlier evidence. Other proteins found are involved in cell-cycle control, ontogenesis, tumor-suppressor genes and anti-apoptotic processes. This is a clear example of how miRNA can have far-reaching influence on the overall function of the cell secondary to its ability to influence several target mRNA by various mechanisms. Small RNA analysis of CLL cells reveals other consistent alterations of miRNA that may be important in the pathogenesis of CLL. These include downregulation of miR-181a, let-7a and miR-30d. Overexpression of miR-155 was also observed. Other novel miRNAs located in chromosome 1 were reported in the same analysis. 62 Another miRNA profile analysis of CLL patients confirms the overexpression of miR-155, but also shows downregulation of miR-150 and miR-92. 63 Although such profiles have been correlated with prognosis, their functional and mechanistic significance remains to be elucidated. miR-29 and miR-181 have been shown to be involved in CLL pathogenesis by altering TCL1 expression. 64 
Acute lymphoblastic leukemia
The first evidence of the involvement of miRNAs in acute lymphoblastic leukemia (ALL) was demonstrated when an insertion of miR-125-1, a human homologue of lin-4, was seen in a rearranged heavy-chain immunoglobulin gene locus in a patient with B-cell ALL. 65 Zanette et al. 66 have carried out a miRNA profiling of ALL and have shown the upregulation of miR-128b, miR-204, miR218, miR-331 and miR-181b-1, apart from miR-17-92 cluster. Mi et al. 67 have shown a distinct miRNA signature in patients with ALL. The functional significance of these alterations has yet to be explored.
Acute myeloid leukemia
An association between miRNA signatures and cytogenetics was shown by Garzon et al. 68 In this study miRNA expression patterns were correlated with molecular abnormalities like t(11q23), trisomy 8 and FLT3-ITD mutations. Specific miRNA alterations were also correlated with prognosis. Patients with a high expression of miR-191 and miR-199a had worse overall and event-free survival. A different signature was also generated and validated by Marcucci et al. 69 This analysis generated a miRNA summary value that proved to be a significant independent predictor of survival. Another study reported recently by Dixon-McIver et al. 70 reported specific miRNA signatures that correlate with specific karyotypic alterations in acute myeloid leukemia, apart from a general set of miRNA that were deregulated across the entire leukemic set. For example, t(15;17) translocation was associated with an upregulation of miR-127, miR-154, miR-154, miR-299, miR-323, miR-368 and miR-370. Apart from distinct miRNA signatures for diagnosis and prognosis, the functional effects of some alterations have also been shown. For example, with overexpression of miR-155, mice developed an expansion of the granulocyte/monocyte population with pathological features characteristic of myeloid neoplasia. 71 This clinically correlates with FLT3-ITD þ samples that show an upregulation of miR-155. 72 Also, acute myeloid leukemia patients carrying NPM1 mutations show a downregulation of miR-204 (among other specific alterations). The investigators also showed that miR-204 targets HOXA10 and MEIS1, suggesting that the HOX upregulation seen in these patients may be secondary to miRNA alterations. Some evidence linking ALL1 fusion protein to miRNA alterations through targeting DROSHA has also been postulated.
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Chronic myelogenous leukemia
Venturini et al. 74 showed that the miR17-92 cluster is regulated by the BCR-ABL and c-MYC. Knockdown of c-MYC in cell lines leads to a decrease in expression of the cluster. Upregulation of the cluster occurs in both chronic myelogenous leukemia (CML) and chronic-phase patients but not in blast-crisis CML. Also, in CML, loss of a 7-Mb region that encodes 12% of all genomic miRNAs has been found. This region also includes miR-203, the loss of which upregulates ABL-1.
miRNAs provide a potential therapeutic opportunity
The oncologist has to face a double dilemma: how to improve the life expectancy of cancer patients while the majority of chemotherapeutic regimens have side effects and limited efficacy, and the molecular approach (such as antisense oligonucleotides, small-molecule inhibitors, antibodies, vaccines, etc.) is for the most part experimental and at an early clinical stage. One solution is to rely on new discoveries, believing that siRNAs or miRNAs or other yet undiscovered biological molecules could solve the issue. To exemplify one such possible strategy, we will use B-CLL, the most frequent adult leukemia in the Western world 75 and one of the best studied models of interplay between coding and non-coding RNAs in human cancers. 76 Human B-cell CLL is characterized by predominantly non-dividing malignant B cells overexpressing the anti-apoptotic Bcl2 protein. Deletion or downregulation of miR-15a/miR-16-1 cluster located at chromosome 13q14.3 represents an early event directly involved in the regulation of BCL2 expression. 60 During the evolution of malignant clones, other miRNAs are deleted (such as miR-29) or overexpressed (such as miR-21, miR-155 or the cluster miR-221/miR-222), contributing to the aggressiveness of B-CLL. Such abnormalities influence the expression of other protein-coding genes, as was reported that miR-221 and miR-222 directly downmodulate c-KIT receptor and miR-29 regulated the levels of TCL1 oncogene 64 or by targeting other non-coding RNAs such as non-coding UCGs uc.160 and uc.78. 77 The consequences of this steady accumulation of abnormalities are represented initially by a low apoptosis and high survival of malignant B cells and lately by the evolution of more aggressive clones with a higher proliferative capacity and at a molecular level by the overexpression of BCL-2 and TCL1 oncogenes. Therefore, a mixed strategy of targeting both these oncogenes at the same time by using combined RNA drugs could be proposed. For example, using a miRNA that will target both BCL-2 and TCL1 could be an option. Furthermore, using simultaneous systemic delivery of miR-15 and miR-16 family members targeting BCL2, as well as of miR-29 and miR-181 family members targeting TCL1 could increase the efficacy of therapeutic oncogenic downregulation. Taking advantage of the genome-wide profiling technologies, these therapies could be provided to only a subset of CLL patients having both types of lesions, or could be specifically provided only to the patients with BCL2 overexpression and miR15 and miR-16 downregulation (the indolent form of CLL). On the other hand, the therapy may be directed only to the patients with TCL1 overexpression and miR-29 and miR-181 downregulation (the aggressive form of CLL). Although exciting, the use of miRNAs/ anti-miRNAs in human-cancer therapy has still to show high efficiency of target inhibition with significant increase in patient survival and reduced toxic effects.
Conclusion miRNAs control several critical cellular processes and have emerged as a fundamental epigenetic regulatory mechanism. This is true in normal and abnormal cellular states, including cancer. In the past few years there has been a significant expansion of the understanding of the role of these small molecules in the pathogenesis of leukemia. Further studies are needed to define specific processes and molecular interaction to harness this knowledge to improve patient care. These studies have the potential of improving diagnosis, prognostication, provision of biomarkers and the creation of novel therapeutic agents for the treatment of leukemia.
Future directions
New miRNAs and new non-coding RNAs will be discovered by a variety of methods involving microarrays, deep sequencing and cloning. Non-coding RNA networks will be discovered and found to be important in the pathogenesis of all types of leukemias and also in various therapy-related aspects, such as resistance to therapy. The non-coding RNAs will represent a new category of diagnostic markers for cancer patients and for leukemia patients in particular. Non-coding RNA-based gene therapy will be investigated in the near future and, as the delivery issues are less significant, leukemias will be among the first cancers to be tested initially.
